Aptar wins FDA approval for needle-free rescue treatment for severe hypoglycemia.
M2 EQUITYBITES-July 26, 2019-Aptar wins FDA approval for needle-free rescue treatment for severe hypoglycemia
(C)2019 M2 COMMUNICATIONS http://www.m2.com
Drug delivery company AptarGroup Inc (NYSE:ATR) reported on Thursday the receipt of US Food and Drug Administration (FDA) approval for its Unidose Powder System, an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes.
This is the first FDA approval of a prescription drug using Aptar's patented Unidose Powder System and is Aptar's first combination of a drug delivery device with a protective active packaging container.
According to the company, the Unidose Powder System is a single-use, ready-to-use one-step nasal delivery device which can deliver a powder formulation in an emergency situation quickly and easily. During such an event, the patient or caregiver presses a small plunger on the bottom of the device to release the drug in a single powder puff into the nose, where the drug can be quickly absorbed via the nasal mucosa.
The product is an alternative to injectable kits that may require assembly, including a multistep, time-consuming process of mixing powder and liquid.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Jul 26, 2019|
|Previous Article:||Universal Logistics Holdings reports 12.9% higher net income for Q2 and dividend of USD0.105 per share.|
|Next Article:||Virginia Bio hires John Newby as CEO.|